Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Collection of Safety, Efficacy and Resource Utilization Information in Patients Who Have Received Melphalan PHP With the Delcath Hepatic Delivery System for the Treatment of Unresectable Hepatic Malignancy

NCT03266042 is registered in ClinicalTrials.gov with Delcath Systems Inc. as lead sponsor.

NCT NCT03266042
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03266042 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Collection of Safety, Efficacy and Resource Utilization Information in Patients Who Have Received Melphalan PHP With the Delcath Hepatic Delivery System for the Treatment of Unresectable Hepatic Malignancy
Lead sponsor
Delcath Systems Inc.
Phase
Observational
Overall status
Unknown status
Start date
January 14, 2016
Completion date
February 29, 2020
Enrollment
200 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hepatic malignant neoplasm primary non-resectable